[1]
Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. The New England journal of medicine. 1988 Jun 23:318(25):1651-7
[PubMed PMID: 2453802]
[2]
Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood. 1989 Nov 1:74(6):1888-93
[PubMed PMID: 2679910]
[3]
van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet (London, England). 1985 Feb 23:1(8426):425-9
[PubMed PMID: 2857806]
[4]
Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis and rheumatism. 2000 Feb:43(2):414-9
[PubMed PMID: 10693883]
[5]
Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis and rheumatism. 2003 Jun 15:49(3):388-93
[PubMed PMID: 12794795]
Level 3 (low-level) evidence
[6]
Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford, England). 2009 Dec:48(12):1560-5. doi: 10.1093/rheumatology/kep304. Epub 2009 Oct 1
[PubMed PMID: 19797309]
[7]
Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. The New England journal of medicine. 2012 Jul 19:367(3):214-23. doi: 10.1056/NEJMoa1108735. Epub
[PubMed PMID: 22808956]
[8]
Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J, Pinder BD, Zhao A, Zhang J, Tadesse Y, Qian D, Weirauch M, Nair R, Tsoi A, Pagnoux C, Carette S, Chung S, Cuthbertson D, Davis JC Jr, Dellaripa PF, Forbess L, Gewurz-Singer O, Hoffman GS, Khalidi N, Koening C, Langford CA, Mahr AD, McAlear C, Moreland L, Seo EP, Specks U, Spiera RF, Sreih A, St Clair EW, Stone JH, Ytterberg SR, Elder JT, Qu J, Ochi T, Hirano N, Edberg JC, Falk RJ, Amos CI, Siminovitch KA, Vasculitis Clinical Research Consortium. Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2017 May:69(5):1054-1066. doi: 10.1002/art.40034. Epub 2017 Apr 6
[PubMed PMID: 28029757]
Level 2 (mid-level) evidence
[9]
Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder-Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nature medicine. 2008 Oct:14(10):1088-96. doi: 10.1038/nm.1874. Epub 2008 Oct 5
[PubMed PMID: 18836458]
[10]
Savage CO, Gaskin G, Pusey CD, Pearson JD. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Experimental nephrology. 1993 May-Jun:1(3):190-5
[PubMed PMID: 7915959]
[11]
Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. Journal of the American Society of Nephrology : JASN. 2009 Feb:20(2):289-98. doi: 10.1681/ASN.2008050497. Epub 2008 Dec 10
[PubMed PMID: 19073822]
[12]
Radford DJ, Luu NT, Hewins P, Nash GB, Savage CO. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis and rheumatism. 2001 Dec:44(12):2851-61
[PubMed PMID: 11762946]
[13]
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and rheumatism. 2013 Jan:65(1):1-11. doi: 10.1002/art.37715. Epub
[PubMed PMID: 23045170]
Level 3 (low-level) evidence
[14]
Holl-Ulrich K. [Histopathology of systemic vasculitis]. Der Pathologe. 2010 Feb:31(1):67-76. doi: 10.1007/s00292-009-1156-x. Epub
[PubMed PMID: 19533137]
[15]
Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nature reviews. Rheumatology. 2014 Aug:10(8):463-73. doi: 10.1038/nrrheum.2014.103. Epub 2014 Jul 8
[PubMed PMID: 25003769]
[16]
Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmunity reviews. 2014 Nov:13(11):1121-5. doi: 10.1016/j.autrev.2014.08.017. Epub 2014 Aug 20
[PubMed PMID: 25149391]
[17]
Daum TE, Specks U, Colby TV, Edell ES, Brutinel MW, Prakash UB, DeRemee RA. Tracheobronchial involvement in Wegener's granulomatosis. American journal of respiratory and critical care medicine. 1995 Feb:151(2 Pt 1):522-6
[PubMed PMID: 7842215]
[18]
Chang DY, Wu LH, Liu G, Chen M, Kallenberg CG, Zhao MH. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Jun:27(6):2343-9. doi: 10.1093/ndt/gfr643. Epub 2011 Nov 25
[PubMed PMID: 22121235]
[19]
Kallenberg CG. The diagnosis and classification of microscopic polyangiitis. Journal of autoimmunity. 2014 Feb-Mar:48-49():90-3. doi: 10.1016/j.jaut.2014.01.023. Epub 2014 Jan 22
[PubMed PMID: 24461388]
[20]
Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). Journal of autoimmunity. 2014 Feb-Mar:48-49():99-103. doi: 10.1016/j.jaut.2014.01.018. Epub 2014 Feb 12
[PubMed PMID: 24530234]
[21]
van der Geest KSM, Brouwer E, Sanders JS, Sandovici M, Bos NA, Boots AMH, Abdulahad WH, Stegeman CA, Kallenberg CGM, Heeringa P, Rutgers A. Towards precision medicine in ANCA-associated vasculitis. Rheumatology (Oxford, England). 2018 Aug 1:57(8):1332-1339. doi: 10.1093/rheumatology/kex367. Epub
[PubMed PMID: 29045715]
[22]
Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nature reviews. Rheumatology. 2016 Oct:12(10):570-9. doi: 10.1038/nrrheum.2016.123. Epub 2016 Jul 28
[PubMed PMID: 27464484]
[23]
Franssen CF, Huitema MG, Muller Kobold AC, Oost-Kort WW, Limburg PC, Tiebosch A, Stegeman CA, Kallenberg CG, Tervaert JW. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. Journal of the American Society of Nephrology : JASN. 1999 Jul:10(7):1506-15
[PubMed PMID: 10405206]
[24]
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the rheumatic diseases. 2009 Dec:68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3
[PubMed PMID: 19054820]
Level 1 (high-level) evidence
[25]
Koh JH, Kemna MJ, Cohen Tervaert JW, Kim WU. Editorial: Can an Increase in Antineutrophil Cytoplasmic Autoantibody Titer Predict Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis? Arthritis & rheumatology (Hoboken, N.J.). 2016 Jul:68(7):1571-3. doi: 10.1002/art.39639. Epub
[PubMed PMID: 26882278]
Level 3 (low-level) evidence
[26]
Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the rheumatic diseases. 2007 May:66(5):605-17
[PubMed PMID: 17170053]
[27]
Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the rheumatic diseases. 2012 Jun:71(6):955-60. doi: 10.1136/annrheumdis-2011-200477. Epub 2011 Nov 29
[PubMed PMID: 22128076]
[28]
Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, Luqmani R, Mills J, Mooney J, Venning M, Watts RA, BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford, England). 2014 Dec:53(12):2306-9. doi: 10.1093/rheumatology/ket445. Epub 2014 Apr 11
[PubMed PMID: 24729399]
[29]
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. The New England journal of medicine. 2010 Jul 15:363(3):211-20. doi: 10.1056/NEJMoa0909169. Epub
[PubMed PMID: 20647198]
[30]
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010 Jul 15:363(3):221-32. doi: 10.1056/NEJMoa0909905. Epub
[PubMed PMID: 20647199]
[32]
Agnello V, Romain PL. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheumatic diseases clinics of North America. 1996 Feb:22(1):1-21
[PubMed PMID: 8907062]
[33]
Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Annals of the rheumatic diseases. 2015 Jan:74(1):177-84. doi: 10.1136/annrheumdis-2013-203927. Epub 2013 Nov 15
[PubMed PMID: 24243925]
[34]
Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). British journal of rheumatology. 1998 Jan:37(1):57-63
[PubMed PMID: 9487252]
Level 3 (low-level) evidence
[35]
Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford, England). 2002 May:41(5):572-81
[PubMed PMID: 12011383]